Physician profile
Ryan E Tyler
NPI 1336198639
$1,765.13
in general payments reported to CMS, 2019-2025
25 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $36.98 · 2021: $138 · 2022: $281 · 2023: $225 · 2024: $311 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.27 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $229.50 | 2019-2025 | Repatha, Otezla, Evenity |
| Madrigal Pharmaceuticals | $204.18 | 2024-2025 | Resmetirom, Rezdiffra |
| Glaxosmithkline, LLC. | $153.12 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Edwards Lifesciences Corporation | $103.68 | 2021 | |
| Bardy Diagnostics, INC. | $83.35 | 2022 | |
| Abbott Laboratories | $56.54 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $50.47 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $45.12 | 2023 | Vraylar, Viberzi, Linzess |
| Pfizer INC. | $40.23 | 2025 | |
| Sanofi-Aventis U.S. LLC | $39.13 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.97 | 2025 | Caplyta |
| Ferring Pharmaceuticals INC. | $37.44 | 2023-2024 | Rebyota |
| Lilly USA, LLC | $36.68 | 2022-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $31.06 | 2024-2025 | Airsupra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $25.34 | 2025 | Omnipod |
| Medtronic Minimed, INC. | $24.55 | 2020 | |
| Fisher & Paykel Healthcare INC | $20.40 | 2025 | Fisher & Paykel Healthcare |
| Shield Therapeutics INC | $20.00 | 2024 | |
| Inspire Medical Systems, INC. | $18.95 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $18.78 | 2022 | |
| Medtronic, INC. | $17.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.47 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $11.74 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Tyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.